MipSalus’ proprietary technology platform is based on a well-established technology – Molecular Imprinted Polymers (MIPs).
Molecular Imprinted Polymers (MIPs) is a technology that produces antibody-like binding sites in a synthetic polymer by building the polymer matrix around the ligand (“template”). The binding sites in the polymer can be very specific for the selected template molecule and will recognize the template from other closely related structures.
In short, a solution of the template molecule and selected functional monomers is allowed to form the pre-polymerization solution where the functional monomers organize around the template molecule. Subsequently, polymerization is initiated resulting in a solid polymer with the target molecule embedded as single molecules. The solid polymer is then mechanically down-sized into small particles.
Subsequent washing extracts the template molecules leaving cavities in the MIPs particles, which are complementary to the physical and chemical characteristics of the template molecule. These cavities work as binding sites specific for the template molecule.
The initial preparation of MIPs results in a collection of MIPs particles with an uneven distribution of binding sites resulting in only few high-binding particles and many non-binding particles. Thus, without further purification, MIPs have a relatively low overall binding capacity, since only a minor part of the particles contributes to the binding of template molecules.
MipSalus has made significant improvements to the general MIPs technology based on proprietary technology covered by various patent families comprising concept, production and usage. The new approach to refining MIPs expands the potential of the technology significantly and enables its use in various medical applications. The core of MipSalus’ technology is sorting MIPs particles according to their ability to bind the template molecule. By selecting the best binding particles we are able to improve the general template binding properties dramatically. This is crucial in order to make a MIPs-based drug more specifically acting, reduce the dosing level and side effects, and to make a better characterized product necessary to satisfy regulatory requirements.